Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue-Reference-Cited by-同舟云学术

Trastuzumab use in patients with durable complete response in HER2-amplified metastatic breast cancer: to continue or not to continue

Published:2017-12 Issue:12 Volume:28 Page:3098-3099
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Butterbaugh S.T.,Patel R.,Romond E.H.,Mathew A.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/28/12/3098/22295554/mdx532.pdf

Reference5 articles.

1. Her2 positive metastatic breast cancer patient without any sign of recurrence 5 years after cessation of trastuzumab: a case report;Reure;Clin Pharmacol Biopharm,2015

2. Can maintenance trastuzumab be stopped in patients with HER2-positive metastatic breast cancer?;Hsieh;BMJ Case Rep,2015

3. Prolonged complete response after treatment withdrawal in HER2-overexpressed, hormone receptor-negative breast cancer with liver metastases: the prospect of disappearance of an incurable disease;Viel;BMC Cancer,2014

4. Clinical predictors of long-term survival in HER2-positive metastatic breast cancer;Murthy;Breast Cancer Res Treat.,2016

5. Prognosis for patients with metastatic breast cancer who achieve a no-evidence-of-disease status after systemic or local therapy;Bishop;Cancer,2015

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression;Scientific Reports;2023-05-31

2. HER2-Directed Therapy in Advanced Breast Cancer: Benefits and Risks;OncoTargets and Therapy;2023-02

3. No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer;British Journal of Cancer;2021-12-20

4. Dual HER2 Blockade in Neoadjuvant Treatment of HER2+ Breast Cancer: A Meta-Analysis and Review;Technology in Cancer Research & Treatment;2020-01-01